Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 25,356 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 25,356 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $188,395.08. Following the completion of the transaction, the chief executive officer owned 5,937,146 shares in the company, valued at approximately $44,112,994.78. The trade was a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $88,787.60.

Sight Sciences Price Performance

SGHT opened at $7.47 on Wednesday. The firm has a market cap of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $9.24. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $7.52 and its 200 day moving average price is $5.13.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. The company had revenue of $12.54 million for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Lake Street Capital increased their price target on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday. Morgan Stanley upped their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, UBS Group increased their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.30.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares during the period. CWM LLC grew its stake in shares of Sight Sciences by 70.2% in the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after purchasing an additional 3,137 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Sight Sciences by 32.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Sight Sciences in the 2nd quarter worth approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after purchasing an additional 4,453 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.